GS-0272
/ Gilead
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
August 07, 2025
MARASLE: Study of GS-0272 in Participants With Rheumatoid Arthritis
(clinicaltrials.gov)
- P1 | N=87 | Recruiting | Sponsor: Gilead Sciences | Trial completion date: Jun 2025 ➔ Mar 2026 | Trial primary completion date: Jun 2025 ➔ Mar 2026
Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
December 18, 2024
First domestic clinical trial of new autoimmune disease treatment [Google translation]
(Health Korea News)
- "On the 17th, the Ministry of Food and Drug Safety approved the phase 1b clinical trial plan (IND) for Gilead Sciences Korea's 'GS-0272'. The trial will evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of multiple ascending doses of 'GS-0272' in adult participants with rheumatoid arthritis....For reference, the domestic phase 1b clinical trial of 'GS-0272' is scheduled to be conducted at Chungnam National University Hospital, Seoul National University Hospital, and Ajou University Hospital until June next year."
Trial status • Rheumatoid Arthritis
June 17, 2024
MARASLE: Study of GS-0272 in Participants With Rheumatoid Arthritis
(clinicaltrials.gov)
- P1 | N=87 | Recruiting | Sponsor: Gilead Sciences | N=48 ➔ 87
Enrollment change • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
December 15, 2023
MARASLE: Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Gilead Sciences
Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus
November 27, 2023
MARASLE: Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Gilead Sciences | Phase classification: P1b ➔ P1
Phase classification • Immunology • Inflammatory Arthritis • Lupus • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus
October 10, 2023
MARASLE: Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus
(clinicaltrials.gov)
- P1b | N=48 | Recruiting | Sponsor: Gilead Sciences | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus
September 11, 2023
MARASLE: Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus
(clinicaltrials.gov)
- P1b | N=48 | Not yet recruiting | Sponsor: Gilead Sciences
New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus
1 to 7
Of
7
Go to page
1